TScan Therapeutics Announces 2024 Clinical Plans and Highlights Recent Progress
WALTHAM, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced its 2024 clinical pipeline plans and highlighted recent corporate achievements.
- Additionally, we submitted INDs for two additional TCRs in December and the 30-day review period with the FDA is ongoing.
- Plans to complete Phase 1 dosing and report clinical and translational data in 2024, and two-year relapse data in 2025.
- Initiated Phase 1 solid tumor clinical study and expects to dose the first patient in the first quarter of 2024.
- Plans to continue to build ImmunoBank with additional IND filings throughout 2024.